Baystate Medical Center
- Type
- Teaching hospital
- Where
- Springfield, MA
- Medicare CCN
- 220077
- Received
- $770,737 in 144 records, 2021 ($280,908 general, $489,828 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Baystate Medical Center, Inc. Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Patent assignee: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Trademark owner: Baystate Medical Center, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 15 | $280,908 |
| 2021 | Research payment | 129 | $489,828 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 1 | $250,000 | 2021 |
| Roche Products Limited | 28 | $86,794 | 2021 |
| Medtronic, Inc. | 21 | $81,606 | 2021 |
| GlaxoSmithKline, LLC. | 9 | $67,772 | 2021 |
| Hoffmann-La Roche Limited | 12 | $52,610 | 2021 |
| Rhythm Pharmaceuticals, Inc. | 12 | $47,635 | 2021 |
| Genentech, Inc. | 5 | $35,204 | 2021 |
| Janssen Research & Development, LLC | 2 | $29,700 | 2021 |
| ZOLL Circulation Inc | 3 | $26,205 | 2021 |
| Insmed, Inc. | 11 | $22,402 | 2021 |
| Myriad Genetic Laboratories, Inc. | 1 | $12,000 | 2021 |
| Amgen Inc. | 1 | $10,940 | 2021 |
| Gilead Sciences, Inc. | 5 | $9,516 | 2021 |
| AstraZeneca Pharmaceuticals LP | 1 | $8,140 | 2021 |
| GENZYME CORPORATION | 8 | $6,845 | 2021 |
| Celgene Corporation | 3 | $5,850 | 2021 |
| Abbott Laboratories | 6 | $4,460 | 2021 |
| BIOTRONIK INC. | 6 | $3,245 | 2021 |
| bioMerieux Inc | 2 | $3,076 | 2021 |
| Chiesi USA, Inc. | 1 | $2,350 | 2021 |
| Medline Industries LP | 1 | $2,338 | 2021 |
| Janssen Pharmaceuticals, Inc | 1 | $1,000 | 2021 |
| Johnson & Johnson Health Care Systems Inc. | 2 | $813 | 2021 |
| Siemens Medical Solutions USA, Inc. | 1 | $220 | 2021 |
| JAZZ PHARMACEUTICALS INC. | 1 | $10 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 129 | $489,828 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $250,000 |
| Grant | 2 | $20,000 |
| Debt forgiveness | 9 | $6,832 |
| Long term medical supply or device loan | 2 | $3,076 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Medline Industries LP | $2,338 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | bioMerieux Inc | $1,538 | Long term medical supply or device loan | In-kind items and services | ASTUTE 140 METER KIT US (U) Device, Clinical Diagnostics | 2021 | |
| 2021-12-31 | bioMerieux Inc | $1,538 | Long term medical supply or device loan | In-kind items and services | ASTUTE 140 METER KIT US (U) Device, Clinical Diagnostics | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $220 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Rhythm Pharmaceuticals, Inc. | $5,263 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-12-13 | GlaxoSmithKline, LLC. | $1,973 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $1,950 | Research payment | Cash or cash equivalent | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and | 2021 | |
| 2021-12-10 | Rhythm Pharmaceuticals, Inc. | $3,705 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-022 | 2021 |
| 2021-12-09 | Hoffmann-La Roche Limited | $2,574 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-12-03 | Medtronic, Inc. | $1,300 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2021 |
| 2021-12-02 | Celgene Corporation | $1,950 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | Induction Study #1 - A Phase 3, Multicenter, Rando | 2021 |
| 2021-12-02 | Celgene Corporation | $1,950 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | A Phase 3, Multicenter, Randomized, Double-Blind, | 2021 |
| 2021-12-02 | Celgene Corporation | $1,950 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | A Phase 3, Multicenter, Open-Label Extension Study | 2021 |
| 2021-11-22 | GlaxoSmithKline, LLC. | $5,069 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $780 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2021 | |
| 2021-11-19 | Genentech, Inc. | $2,523 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-11-17 | Gilead Sciences, Inc. | $2,500 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2021 |
| 2021-11-15 | Medtronic, Inc. | $10,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-08 | GENZYME CORPORATION | $783 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2021 | |
| 2021-11-08 | GENZYME CORPORATION | $783 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-11-08 | GENZYME CORPORATION | $783 | Research payment | Cash or cash equivalent | MPS-I LSD Data Registry | 2021 | |
| 2021-11-04 | Medtronic, Inc. | $278 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-11-04 | Medtronic, Inc. | $278 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-11-02 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2021 |
| 2021-11-02 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2021 |
| 2021-10-25 | GlaxoSmithKline, LLC. | $5,495 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-10-22 | Janssen Pharmaceuticals, Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-10-18 | GENZYME CORPORATION | $350 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2021 | |
| 2021-10-18 | GENZYME CORPORATION | $350 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-10-18 | GENZYME CORPORATION | $350 | Research payment | Cash or cash equivalent | MPS-I LSD Data Registry | 2021 | |
| 2021-10-06 | ZOLL Circulation Inc | $19,525 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | 2021 | |
| 2021-09-29 | Medtronic, Inc. | $850 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-09-29 | Medtronic, Inc. | $850 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-09-15 | ZOLL Circulation Inc | $3,575 | Research payment | Cash or cash equivalent | Temperature Management System Device, Temperature Management | STEMICOOL | 2021 |
| 2021-09-13 | Genentech, Inc. | $18,384 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-09-13 | GlaxoSmithKline, LLC. | $14,008 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-08-24 | Medtronic, Inc. | $20,164 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2021 |
| 2021-08-24 | Hoffmann-La Roche Limited | $10,245 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-08-24 | Medtronic, Inc. | $4,000 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2021 |
| 2021-08-24 | Hoffmann-La Roche Limited | $650 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-08-24 | Hoffmann-La Roche Limited | $100 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-08-20 | Eli Lilly and Company | $250,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-18 | Rhythm Pharmaceuticals, Inc. | $2,450 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-08-18 | Rhythm Pharmaceuticals, Inc. | $2,210 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-08-18 | Rhythm Pharmaceuticals, Inc. | $1,950 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-014 | 2021 |
| 2021-08-18 | Medtronic, Inc. | $1,700 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-08-18 | Medtronic, Inc. | $1,700 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-08-18 | Rhythm Pharmaceuticals, Inc. | $650 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-08-17 | Abbott Laboratories | $750 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-08-10 | BIOTRONIK INC. | $351 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2021 |
| 2021-08-10 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2021 |
| 2021-08-10 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2021 |
| 2021-07-29 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-07-29 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-07-29 | Insmed, Inc. | $350 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-07-12 | GlaxoSmithKline, LLC. | $3,474 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-07-09 | Medtronic, Inc. | $4,998 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-07-09 | Medtronic, Inc. | $4,998 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-07-06 | Hoffmann-La Roche Limited | $1,300 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-07-06 | Hoffmann-La Roche Limited | $650 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-07-01 | Hoffmann-La Roche Limited | $650 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-06-25 | Janssen Research & Development, LLC | $27,750 | Research payment | Cash or cash equivalent | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and | 2021 | |
| 2021-06-23 | Gilead Sciences, Inc. | $1,546 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2021 |
| 2021-06-21 | Johnson & Johnson Health Care Systems Inc. | $142 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-14 | GlaxoSmithKline, LLC. | $8,257 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-06-14 | Insmed, Inc. | $52 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $8,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $4,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $3,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $3,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $1,950 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $425 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-06-04 | Insmed, Inc. | $125 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-05-19 | Gilead Sciences, Inc. | $3,644 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2021 |
| 2021-05-14 | Medtronic, Inc. | $10,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-05-13 | Medtronic, Inc. | $721 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-05-13 | Medtronic, Inc. | $721 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-05-11 | Abbott Laboratories | $750 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-04-29 | Abbott Laboratories | $833 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-04-29 | Abbott Laboratories | $660 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-04-26 | GlaxoSmithKline, LLC. | $8,883 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-04-26 | Rhythm Pharmaceuticals, Inc. | $4,670 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-04-23 | AstraZeneca Pharmaceuticals LP | $8,140 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2021 |
| 2021-04-19 | GlaxoSmithKline, LLC. | $7,534 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-04-12 | Chiesi USA, Inc. | $2,350 | Research payment | Cash or cash equivalent | CUROSURF Drug, NEONATOLOGY | 2021 | |
| 2021-04-01 | Roche Products Limited | $17,304 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-04-01 | Roche Products Limited | $2,768 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-04-01 | Roche Products Limited | $1,457 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-04-01 | JAZZ PHARMACEUTICALS INC. | $10 | Research payment | Cash or cash equivalent | XYWAV Drug, NEUROLOGY | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2021 |
| 2021-03-30 | Genentech, Inc. | $4,205 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-03-25 | Medtronic, Inc. | $1,225 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-03-25 | Medtronic, Inc. | $1,225 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-03-23 | BIOTRONIK INC. | $2,300 | Research payment | Cash or cash equivalent | Linoxsmart Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2021 |
| 2021-03-23 | Hoffmann-La Roche Limited | $1,800 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-23 | Medtronic, Inc. | $1,681 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2021 | |
| 2021-03-23 | Medtronic, Inc. | $1,681 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2021 | |
| 2021-03-22 | Rhythm Pharmaceuticals, Inc. | $6,500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-014 | 2021 |
| 2021-03-22 | Rhythm Pharmaceuticals, Inc. | $6,500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-014 | 2021 |
| 2021-03-22 | Rhythm Pharmaceuticals, Inc. | $5,300 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-022 | 2021 |
| 2021-03-17 | Hoffmann-La Roche Limited | $850 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-17 | Hoffmann-La Roche Limited | $100 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-15 | Gilead Sciences, Inc. | $150 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2021 |
| 2021-03-12 | Rhythm Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-03-11 | Roche Products Limited | $639 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-03-10 | ZOLL Circulation Inc | $3,105 | Research payment | Cash or cash equivalent | Temperature Management System Device, Temperature Management | STEMICOOL | 2021 |
| 2021-03-09 | Hoffmann-La Roche Limited | $9,338 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-05 | Genentech, Inc. | $8,410 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-02-25 | Hoffmann-La Roche Limited | $24,353 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-02-25 | Roche Products Limited | $8,429 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-25 | Roche Products Limited | $8,056 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-25 | Roche Products Limited | $6,211 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-25 | Roche Products Limited | $6,056 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-25 | Roche Products Limited | $473 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-24 | Myriad Genetic Laboratories, Inc. | $12,000 | Research payment | Cash or cash equivalent | EndoPredict Device, Tumor DNA Genetic Oncology Analysis | EndoPredict Extended Endocrine Trial (EXET) | 2021 |
| 2021-02-23 | Johnson & Johnson Health Care Systems Inc. | $671 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-22 | GENZYME CORPORATION | $2,665 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-02-21 | Roche Products Limited | $6,900 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-21 | Roche Products Limited | $4,539 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-20 | Amgen Inc. | $10,940 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625-VESALIUS - CV | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | $1,676 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2021 |
| 2021-02-16 | GlaxoSmithKline, LLC. | $13,075 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2021 | |
| 2021-02-16 | Roche Products Limited | $500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-16 | Roche Products Limited | $500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-16 | Roche Products Limited | $350 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-09 | Roche Products Limited | $1,500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-09 | Roche Products Limited | $100 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-02-08 | Medtronic, Inc. | $6,617 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-02-08 | Medtronic, Inc. | $6,617 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-01-26 | Roche Products Limited | $6,741 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-26 | Roche Products Limited | $2,778 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-26 | Roche Products Limited | $1,596 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-26 | Roche Products Limited | $1,300 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-26 | Roche Products Limited | $650 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-26 | Roche Products Limited | $400 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-26 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-22 | Rhythm Pharmaceuticals, Inc. | $8,037 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-023 | 2021 |
| 2021-01-22 | Genentech, Inc. | $1,682 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-01-19 | Roche Products Limited | $6,046 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-19 | Roche Products Limited | $500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-19 | Abbott Laboratories | $466 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-01-19 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-19 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-19 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2021 |
| 2021-01-07 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Springfield, MA, county Hampden County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Springfield, MA | County Hampden County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 154,749 | 462,815 | 7,044,056 |
| Population, 2020 census P1 | 155,929 | 465,825 | 7,029,917 |
| Median age B01002 | 33.7 | 40.0 | 40.0 |
| Under 18 B01001 | 24.2% | 20.9% | 19.4% |
| 65 and over B01001 | 13.2% | 18.3% | 17.9% |
| Households B11001 | 57,772 | 184,471 | 2,785,042 |
| Foreign born B05002 | 10.5% | 9.4% | 18.0% |
| Median household income B19013 | $52,656 | $71,306 | $103,960 |
| Median family income B19113 | $66,045 | $91,397 | $131,675 |
| Per capita income B19301 | $27,337 | $38,219 | $57,897 |
| Poverty rate B17001 | 25.8% | 16.3% | 10.0% |
| Unemployment rate B23025 | 8.7% | 6.0% | 5.2% |
| Civilian labor force B23025 | 69,390 | 226,771 | 3,911,446 |
| Mean commute (minutes) B08013 | 20.2 | 22.7 | 29.1 |
| Bachelor's degree or higher B15003 | 20.5% | 29.3% | 47.3% |
| Housing units B25001 | 62,217 | 197,591 | 3,030,406 |
| Owner-occupied B25003 | 49.6% | 62.2% | 62.5% |
| Renters B25003 | 50.4% | 37.8% | 37.5% |
| Median home value B25077 | $245,000 | $298,800 | $562,100 |
| Median gross rent B25064 | $1,144 | $1,136 | $1,762 |
| White, not Hispanic B03002 | 27.8% | 59.3% | 66.6% |
| Black B03002 | 17.5% | 7.6% | 6.4% |
| Hispanic or Latino B03002 | 48.6% | 27.0% | 13.3% |
| Asian B03002 | 2.7% | 2.5% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, MA.
Comments